Sanofi (NASDAQ: SNY) announced this week promising results from a Phase IIb study of its OX40-ligand blocker, amlitelimab, in patients with moderate to severe atopic dermatitis. The study focused on participants who demonstrated a favorable response after an initial 24-week treatment period. Following a subsequent 28-week maintenance or withdrawal phase, 69.2% of those who continued treatment and 58.8% of those who were withdrawn from amlitelimab maintained a positive response, indicating the potential for a patient-friendly 12-week dosing regimen.
Additionally, biomarkers such as TARC, eosinophils, and IL-22 remained significantly reduced throughout the trial, even among participants who had been withdrawn from the treatment, where amlitelimab levels in the blood were negligible. This suggests that the drug may provide durable disease control by restoring the balance between pro-inflammatory and regulatory T-cells. Importantly, amlitelimab was also reported to be well-tolerated among participants.
Sanofi believes that amlitelimab has the potential to become a first- or best-in-class treatment for various conditions, including atopic dermatitis, asthma, hidradenitis suppurativa, scleroderma, celiac disease, and alopecia.- Flcube.com
